In comparison, patients eligible for the TheraP trial had PSMA-positive disease with an SUVmax ≥20 at a site of disease and >10 at all other measurable sites of metastatic disease and no sites of metastatic disease with discordant [18F]FDG-positive and PSMA-negative findings (78). The gene discussed is FOLH1; the disease is metastatic neoplasm.